First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and with Endocrine Therapy in Subjects with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer
Condition: Breast Cancer
Sponsor: Regor Pharmaceuticals Inc.
Full Title
First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and With Endocrine Therapy in Subjects With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer
Study Treatment
RGT-419B, an oral CDK2/4/6 inhibitor
Eligibility/Info
- HR+, HER2- breast cancer with progressive disease after at least 1 line of therapy including a CDK4/6 inhibitor
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
